Llwytho...
Optimizing biologic treatment in IBD: objective measures, but when, how and how often?
BACKGROUND: The advent of biologic agents for the treatment of inflammatory bowel disease (IBD) was accompanied in parallel with emerging understanding of persisting underlying inflammation and ensuing bowel damage that can occur even in patients with seeming clinical remission. This lead to the con...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | BMC Gastroenterol |
|---|---|
| Prif Awduron: | , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
BioMed Central
2015
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4683713/ https://ncbi.nlm.nih.gov/pubmed/26678147 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12876-015-0408-x |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|